Keyphrases
Chronic Lymphocytic Leukemia
87%
Tumor Protein p53 (TP53)
50%
Derepression
50%
Differentially Expressed microRNAs
50%
Hematological Malignancies
50%
Breast Cancer Brain Metastasis
50%
Brain Metastases
50%
Adverse Outcomes
50%
B-cell Lymphoma 2 (Bcl-2)
50%
MicroRNA
50%
Patient Survival
50%
Prognostic Biomarker
37%
Multiple Myeloma
37%
Exosomal microRNA
25%
Neurological Diseases
25%
Exosomes
12%
Drug Delivery Vehicle
12%
Recipient Cells
12%
City Hospitals
12%
Clinical Applicability
12%
Transcriptome
12%
Exosome microRNAs
12%
Glyco
12%
Unmet Medical Need
12%
Metastatic Process
12%
MiR-202
12%
MiRNA Expression
12%
Pathway Enrichment
12%
University of Liverpool
12%
Significance Analysis of Microarrays
12%
Expression Assay
12%
Survival Methods
12%
Prognostic Tool
12%
Prognostic Role
12%
C-Met
12%
MET Oncogene
12%
Metastasis-free Survival
12%
MiR-150-5p
12%
MiR-199a-5p
12%
NanoString nCounter
12%
MiR-132-3p
12%
Kaplan-Meier Survival
12%
MiR-155-5p
12%
Peterborough
12%
Diagnostic Tool
12%
Bridging the Gap
12%
Metastasis
12%
Oncology
12%
Neurology
12%
Cancer Research
12%
Medicine and Dentistry
microRNA
100%
Brain Metastasis
50%
Breast Cancer
50%
Hematologic Malignancy
40%
B-Cell Chronic Lymphocytic Leukemia
30%
Biological Marker
30%
Multiple Myeloma
30%
Exosome
20%
Neurologic Disease
20%
Transcriptome
10%
Galectin 3
10%
Drug Delivery Vehicle
10%
Oncology
10%
Neurology
10%
Malignant Neoplasm
10%
Cancer Research
10%
Cell Signaling Pathway
10%
Significance Analysis of Microarrays
8%
microRNA 132
8%
Oncogene
8%
microRNA 155
8%
Metastasis Free Survival
8%
Overall Survival
8%
Metastatic Carcinoma
8%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
80%
Messenger RNA
50%
Adverse Outcome
50%
microRNA
50%
Hematologic Malignancy
40%
Biological Marker
30%
Multiple Myeloma
30%
Neurologic Disease
20%
Malignant Neoplasm
20%
Drug Delivery Vehicle
10%
Transcriptome
10%
Galectin 3
10%
Protein P53
5%
Survival Time
5%